Yong-Chen “William” Lu is an Assistant Professor in the Department of in the Department of Pathology at the University of Arkansas for Medical Sciences (UAMS). He received his Ph.D. training at Princess Margaret Cancer Centre, University of Toronto, Canada. After finishing his Ph.D. training, he became a postdoctoral visiting fellow at Surgery Branch, National Cancer Institute (NCI), National Institutes of Health (NIH). He was promoted to a staff scientist position, prior to joining the UAMS in early 2021.
Dr. Lu’s research focuses on the development of effective T cell-based immunotherapies for patients with metastatic cancers. He has played a pivotal role in the successful cancer treatments using the T-cell therapies targeting shared cancer antigens or patient-specific mutated antigens. In recent years, he utilizes single-cell sequencing technologies to facilitate the development of new T-cell therapies against cancer.
Lu YC*, Zheng Z, Lowery FJ, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. Journal for ImmunoTherapy of Cancer, a journal of the Society for Immunotherapy of Cancer. (2021) 9:e00259.
Pasetto A*, Lu YC*. Single-cell TCR and transcriptome analysis: An indispensable tool for studying T-cell biology and cancer immunotherapy. Frontiers in Immunology. (2021) 12:689091.
Lu YC*, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA*. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy. Cancer Immunology Research, a journal of the American Association for Cancer Research. (2019) 7(11):1824-1836.
Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA, Lu YC*. Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer. Journal of Immunology, a journal of American Association of Immunologists. (2019) 202(12):3458-3467.
Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nature Communications. (2019) 10(1):449.
Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nature Medicine. (2018) 24(6):724-730.
Lu YC*, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, Fitzgerald PC, Rosenberg SA*. An efficient single-cell RNA-seq approach to identify neoantigen-specific T Cell receptors. Molecular Therapy, a journal of the American Society of Gene Therapy. (2018) 26(2):379-389.
Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. Journal of Clinical Oncology, a journal of the American Society of Clinical Oncology. (2017) 35(29):3322-3329.
Complete list of published work at My Bibliography